Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Alendronic Acid for Alveolar Bone Remodeling After Tooth Extraction
NCT05602493Phase 3Active, not recruiting
- Sponsor
- Xeolas Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alveolar bone loss comparing Soludronate Group with Placebo Group (2 arms). Primary endpoint: Buccal and lingual vertical and horizontal bone socket dimensions at 3.5 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
Soludronate
03
Conditions
Alveolar bone loss
Beyond the preview
Go deeper on NCT05602493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602493.